期刊文献+

siRNA介导表皮生长因子受体基因沉默导致HepG2凋亡 被引量:1

SiRNA mediated silencing of the epidermal growth factor receptor induces the apoptosis of HepG2
下载PDF
导出
摘要 目的:研究含有与EGFR基因序列相同的19nt序列RNAi质粒针对HepG2细胞表皮生长因子受体的RNA干扰效果。方法:用pSIREN-hE转染细胞,其质粒骨架为RNAi-Ready pSIREN-Shuttle Vector,含有可以被U6启动子转录成shRNA的寡核苷酸链,大小为69 nt,含有2段19nt的寡核苷酸,用于编码EGFR基因的RNA干扰的siRNA的正义链及反义链,评价该RNAi质粒对人肝细胞癌细胞株(HepG2)EGFR基因的mRNA表达抑制效果及对细胞凋亡的作用。结果:HepG2细胞EGFR基因的mRNA被明显抑制并伴有凋亡增加。结论:含有与EGFR基因序列相同序列RNA质粒对EGFR基因的RNA干扰可能是治疗肝细胞癌的一种有效手段。 Objective: To evaluate the RNAi efficiency of siRNA plasmid on the EGFR gene in a HepG2 cell line. Methods: By using a plasmid vector containing duplex of oligonucleotides, in which 19nt specific sequence of EG-FR expressing cassette to induce RNAi, the expression of endogenous EGFR in HepG2 human hepatocarcinoma cells was suppressed. The HepG2 cells were transfected with pSIREN-hE consisting of a RNAi-ready pSIREN-shuttle vector and duplex of oligonucleotides, which were built up of 69nt base pair, into a 19nt specific sequence of EGFR expressing cassette that can be transcripted by promoter U6. Results: The mRNA of EGFR in HepG2 human hepatocarcinoma cells was decreased and cell proliferation was reduced due to the induction of apoptosis. Conclusion: siRNA-mediated inhibition of EGFR gene may be a useful approach in the treatment of human hepatocarcinoma.
出处 《山东大学学报(医学版)》 CAS 北大核心 2007年第3期313-316,321,共5页 Journal of Shandong University:Health Sciences
关键词 表皮生长因子受体 信使核糖核酸 RNA干扰 细胞凋亡 Epidermal growth factor receptor mRNA RNA interference Apoptosis
  • 引文网络
  • 相关文献

参考文献12

  • 1Duxbury MS.RNA interference:A practical approach[J].J Surg Res,2004,117:339-344.
  • 2Chi JT,Chang HY,Wang NN,et al.Genome wide view of gene silencing by small interfering RNAs[J].Proc Nat Acad Sci USA,2003,100:6 343-6 346.
  • 3Jorissen RN,Walker F,Pouliot N.Epidermal growth factor receptor:mechanisms of activation and signaling[J].Experimental Cell Research,2003,284:31-53.
  • 4Woodburn JR.The epidermal growth factor receptor and its inhibition in cancer therapy[J].Pharmacol Ther,1999,82:241-250.
  • 5Mendelsohn J.Blockade of receptors for growth factors:An anticancer therapy[J].Clin Cancer Res,2000,6(3):747-753.
  • 6Ciardiello F,Ma B.EGF receptor blockade with monoclonal antibodis and so-called "small molecules"[J].Onkologie,2005,28(Suppl 4):18-24.
  • 7Hoekstra R,Dumez H,Eskens FA.Phase I and pharmacologic study of PKI166,an epidermal growth factor receptor tyrosine kinase inhibitor,in patients with advanced solid malignancies[J].Clin Cancer Res,2005,11(19 Pt 1):6 908-6 915.
  • 8Emiliano KC,Eric KR.Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor[J].Current Oncology Reports,2005,7:123-128.
  • 9Yang EB,Wang DF,Mack P.EGF receptor in human Chang liver and hepatoma HepG2 cells[J].Biolchem Mol Biol Int,1996,38(4):813-820.
  • 10F.奥斯伯,R.布伦特..精编分子生物学指南[M]..北京:北京科学出版社,,2001..13-21..

同被引文献19

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 [J]. CA Cancer J Clin, 2010, 60(5) :277-300.
  • 2Herbst R S, Shin D M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy [ J ]. Cancer, 2002, 94 ( 5 ) : 1593-1611.
  • 3Kamel-Reid S, Chong G, Ionescu D N, et al. EGFR tyro- sine kinase mutation testing in the treatment of non-small- cell lung cancer[J]. Curr Oncol, 2012, 19(2) :e67-74.
  • 4Fire A,Xu S, Montgomery M K,et al. Potent and specific genetic interference by double-stranded RNA in caenorhab- ditis elegans[J]. Nature, 1998, 391 (6669) :806-811.
  • 5Zhang S, Tian H, Jiang Q, et al. Suppression of epider- mal growth factor receptor (EGFR) expression by small hairpin RNA inhibits the growth of human nonsmall cell lung cancers bearing wild-type and mutant EGFR[J]. Cancer Invest, 2011, 29(10) :701-708.
  • 6von Eije K J, ter Brake O, Berkhout B. Human immunod- eficiency virus type I escape is restricted when conserved genome sequences are targeted by RNA interence[J]. J Virol, 2008, 82 (6) :2895-2903.
  • 7Ploner C, Rainer J, Niedergger H, et al. The BCL2 rheo- stat in glucocorticoid-induced apoptosis of acute lympho- blatic leukemia[J]. Leukemia, 2008, 22(2) :370-377.
  • 8Shepherd F A, Rodrigues P J, Ciuleanu T, et al. Erlotinib in previously treated non- small-cell lung cancer [J]. N Engl J Med, 2005, 353(2) :123-132.
  • 9Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for Europe- an patients with advanced EGFR mutation-positive non- small-cell lung cancer (EURTAC) : a multicentre, open- label, randomised phase 3 trial [J]. Lancet Oncol, 2012,13 (3) :239-246.
  • 10Klapdor R, Klapdor S, Bahlo M. Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9[J]. Anticancer Res, 2012, 32(5 ) :2191-2197.

引证文献1

相关主题

;
使用帮助 返回顶部